Last reviewed · How we verify
NCT03531008: HEP2
Human Epilepsy Project 2: Resistant Focal Seizures Study
trial in Epilepsy in 157 participants. Completed in 30 September 2022.
30 July 2022
Quick facts
| Lead sponsor | Epilepsy Foundation of America |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 157 |
| Start date | 7 May 2018 |
| Primary completion | 30 July 2022 |
| Estimated completion | 30 September 2022 |
| Sites | 10 locations across United States |
Conditions studied
- Epilepsy — all drugs for Epilepsy →
- Brain Diseases — all drugs for Brain Diseases →
- Central Nervous System Diseases — all drugs for Central Nervous System Diseases →
- Nervous System Diseases — all drugs for Nervous System Diseases →
Sponsor
Epilepsy Foundation of America
Who can join
Adults 16 to 65, any sex, with Epilepsy or Brain Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The HEP2 study is designed to better understand the challenges of living with focal seizures that do not respond to medication, by following 205 people with medication-resistant focal epilepsy over two years to measure changes in health status, healthcare costs, quality of life, and biomarkers of epilepsy severity and treatment response.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03531008
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Epilepsy
Currently open trials in the same condition.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
- NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
- NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
- NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting
Other Epilepsy Foundation of America trials
Trials by the same sponsor.
- NCT06265103 — Epilepsy Learning Healthcare System (ELHS) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03531008 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Epilepsy Foundation of America
- Last refreshed: 18 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03531008.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing